Clinical Research on Diabetic Nephropathy and Chronic Kidney Disease (CKD) and ESRD
For the nephrology population we have:
Kadmon KD019-101 - The purpose of this study is to find out if the experimental drug, KD019, is safe as a possible treatment of ADPKD at various doses. Phase 1 was to determine the safety of the drug and to determine the maximum tolerated dose. Phase 2 will use the selected best dose to see how effective KD019 is at treating ADPKD.
MENTOR - This study will determine whether rituximab is non inferior to cyclosporine in inducing long-term remission of proteinurea in patients with idiopathic membranous nephropathy with less side effects.